Virtual Exhibitions of 23 Museums Lands on the Alipay Platform to Enhance Engagement with Mobile-Savvy Audience
18.5.2022 10:46:00 EEST | Business Wire | Press release
On International Museum Day 2022, 4DAGE announced it landed virtual tours and exhibitions of 23 museums, including the historic Henan Museum and Zhejiang Provincial Museum in China and the Hetjens Museum in Germany, through a mini program on Alipay, the leading digital open platform. The collaboration between 4DAGE and Alipay provides China’s mobile-savvy audience an opportunity to better engage with and learn about the museums’ rich histories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005528/en/
A large bronze mask from China’s “Sanxingdui Ruins” displayed in the Sichuan Museum’s Bronze Age exhibition; from the virtual tour on the Alipay platform (Photo: Business Wire)
The mini program “Yunshang Mibao” (translated as “treasure hunting on the cloud”) launched on the Alipay platform provides users an immersive museum-visiting experience at their fingertips. They can appreciate the beauty of cultural relics in 3D and have a comprehensive tour of historical collections with Chinese narration.
These virtual exhibitions cover a wide range of subjects spanning 8,000 years of history, including Bronze Age civilization in the Yangtze river valley, dinosaurs in the Mesozoic Era and ceramics in the Rococo period.
“We are delighted to collaborate with museums and the Alipay platform to explore innovative ways to communicate the stories and histories of culture institutions to a wider range of museum and art lovers,” said Shen Ming, Director of International Cooperation from 4DAGE, the VR technology provider for the virtual tours.
“Alipay is committed to supporting the digital operations of brands and merchants to enhance their connection and engagement with consumers in China. Together with our partners, we are exploring digital solutions to meet museums’ evolving needs, including leveraging technology to bring their stories to a younger generation and open new commercialization opportunities,” said Xiaoqi Wang, Head of digital operations for culture and tourism sector at Alipay.
The partnership between 4DAGE and Alipay reflects Alipay’s continued commitment to help museums globally engage and deepen their relationship with China’s growing cultural arts and history community at time when international travel is affected by the COVID-19 pandemic.
To further celebrate this year’s International Museum Day, 28 Chinese museums are issuing newly launched creative digital collectibles on the Alipay mini program and the Topnod app, an Ant Group platform for collecting, exploring, and sharing digital collectibles.
A UNESCO report published in May 2020 showed the global museum industry has been severely impacted by COVID-19 with nearly 90% of museums worldwide closing their doors during the pandemic1. However, less than 20% of museum collections were available online, according to a report by the Network of European Museum Organisations in July 20202. Facing the pressing challenges brought by the pandemic, a growing number of museums start to leverage digital platforms and solutions, including online exhibitions, digital tours, and even livestreaming and blockchain technology powered digital collectibles, to better engage with museum lovers.
Including today’s announcement and a recent collaboration with nine Italian museums, over 2,000 museums have landed on the Alipay platform to enhance their digital operations and better connect with museum lovers. These museums are utilising at least one of the digital tools and services available on Alipay, such as mini programs, lifestyle accounts, and blockchain-powered digital collectibles.
About 4DAGE
Founded in 2014, 4DAGE has been dedicated to the studies and application of artificial intelligence in the field of three-dimensional digital reconstruction. As one of the first 3D digital reconstruction centers in China and one of the pioneering companies in 3D display technologies, 4DAGE provides products and solutions to major museums and expositions globally, including the Palace Museum, Nanchang Han Dynasty Haihunhou Historic Site Museum and World Expo. 4DAGE also serves industries ranging from industrial intelligence and smart city to real estate and new retail.
About Alipay
In the evolving digital era, Alipay has transformed from a payment tool of public trust to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operation, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than 1 billion consumers via Alipay’s open platform services.
1
https://cimam.org/documents/102/Museums_around_the_world_in_the_face_of_COVID-19_-_UNESCO_Biblioteca_Digital.pdf
2
https://icom.museum/en/news/online-learning-teaching-digitised-collections/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005528/en/
Contact information
Bell Wang
Email: yixing.wl@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
